Skip to main content
SpringerLink
Log in

Platelet-Activating Factor

  • Chapter
Multiple Organ Failure

  • 365 Accesses

Abstract

Research leading to the discovery of platelet-activating factor (PAF) came from studying a reaction that triggered platelets to release histamine. It was attributed to a factor actively released from leukocytes. Platelet-activating factor was first identified by Benveniste et al. in 1972.1 Later it was recognized that this phospholipid mediator is also released from a number of other cell types, such as macrophages, basophils, and mast cells and that it displayed diverse immunomodulatory actions. The role PAF plays in the process leading to sepsis has especially attracted attention. PAF was identified as an important factor in sepsis leading to the release of many other inflammatory mediators.2

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Benveniste J, Henson PM, Cochrane CG: Leukocyte-dependent histamine release from rabbit platelets: the role of IgE, basophils, and a platelet-activating factor. J Exp Med 1972; 136: 1356–1377.

    Article  PubMed  CAS  Google Scholar 

  2. Braquet P, Paubert-Braquet M, Bourgain RH, Bussolino F, Hosford D: PAF/cytokine auto-generated feedback networks in microvascular immune injury: consequences in shock, ischemia and graft rejection. J lipid Med 1989; 1: 75–112.

    CAS  Google Scholar 

  3. Braquet P, Touqui L, Shen TY, Vargaftig BB: Perspectives in platelet-activating factor research. Pharmacol Rev 1987; 39: 97–145.

    PubMed  CAS  Google Scholar 

  4. Heymans F, Michel E, Borrel MC, et al: New total synthesis and high resolution 1H NMR spectrum of platelet-activating factor, its enantiomer and racemic mixtures. Biochim Biophys Acta 1981; 666: 230–237.

    Article  PubMed  CAS  Google Scholar 

  5. Venable ME, Olson SC, Nieto ML, Wykle RL: Enzymatic studies of lyso platelet-activating factor acylation in human neutrophils and changes upon stimulation. J Biol Chem 1993; 268: 7965–7975.

    PubMed  CAS  Google Scholar 

  6. Hanahan DJ: The continuing biochemical challenge of PAF and closely related lipid mediators. Adv Exp Med Biol 1996; 416: 1–3.

    PubMed  CAS  Google Scholar 

  7. Gomez-Cambronero J, Durstin M, Molski TF: Calcium is necessary but not sufficient for the platelet-activating factor release in human neutrophils stimulated by physiological stimuli: tirole of G-proteins. J Biol Chem 1989; 264: 12699–12704.

    PubMed  CAS  Google Scholar 

  8. Marquis O, Robaut C, Cavero I: Evidence for the existence and ionic modulation of platelet-activating factor receptors mediating degranulatory responses in human polymorphonuclear leuko cytes. J Pharmacol Exp Ther 1989; 250: 293–300.

    PubMed  CAS  Google Scholar 

  9. Ayala A, Chaudry IH: Platelet activating factor and its role in trauma, shock, and sepsis. New Horiz 1996; 4: 265–275.

    PubMed  CAS  Google Scholar 

  10. Zimmerman GA, Lorant DE, McIntyre TM, Prescott SM: Juxtacrine intercellular signaling: another way to do it. Am J Respir Cell Mol Biol 1993; 9: 573–577.

    Article  PubMed  CAS  Google Scholar 

  11. Stafforini DM, McIntyre TM, Carter ME, Prescott SM: Human plasma platelet-activating factor acetylhydrolase: association with lipoprotein particle and role in the degradation of platelet-activating factor. J Biol Chem 1987; 162: 4214–4222.

    Google Scholar 

  12. Elstad MR, Staifforini DM, McIntyre TM, Prescott SM, Zimmerman GA: Platelet-activating factor acetylhydrolase increases during macrophage differentiation: a novel mechanism that regulates accumulation of platelet-activating factor. J Biol Chem 1989; 264: 8467–8470.

    PubMed  CAS  Google Scholar 

  13. Satoh K, Imaizumi T, Kawamura Y, et al: Platelet-activating factor (PAF) stimulates the production of PAF acetylhydrolase by the human hepatoma cell line, HepG2. J Clin Invest 1991; 87: 476–481.

    Article  PubMed  CAS  Google Scholar 

  14. Patrick DA, Moore EE, Moore FA, Biffl WL, Bamett CC: Reduced PAF-acetylhydrolase activity is associated with post-injury multiple organ failure. Shock 1997; 7: 170–174.

    Article  Google Scholar 

  15. Graham RM, Stephens CJ, Silvester W, Leong LL, Sturm MJ, Taylor RR: Plasma degradation of platelet-activating factor in severely ill patients with clinical sepsis. Crit Care Med, 1994; 22: 204–212.

    Article  PubMed  CAS  Google Scholar 

  16. Prescott SM, Zimmerman GA, McIntyre TM: Platelet-activating factor. J Biol Chem 1990; 265: 17381–17384.

    PubMed  CAS  Google Scholar 

  17. Satoh K, Imaizumi T, Yoshida H, Hiramoto M, Takamatsu S: Increased levels of blood platelet-activating factor (PAF) and PAF-like lipids in patients with ischemic stroke. Acta Neurol Scand 1992; 85: 122–127.

    Article  PubMed  CAS  Google Scholar 

  18. Domingo MT, Spinnewynn B, Chabrier PE, Braquet P: Presence of specific binding sites for platelet activating factor (PAF) in brain. Biochem Biophys Res Commun 1988; 151: 730–736.

    Article  PubMed  CAS  Google Scholar 

  19. Anderson BO, Bensard DD, Harken AH: The role of platelet activating factor and its antagonists in shock, sepsis and multiple organ failure. Surg Gynecol Obstet 1991; 172: 415–424.

    PubMed  CAS  Google Scholar 

  20. Touqui L, Jacquemin C, Dumarey C, Vargaftig BB: 1-O-Alkyl-2-alkyl-2-acyl-sn-glycero-3-phosphocholine is the precursor of platelet-activating factor in stimulated rabbit platelets: evidence for an alkylacetyl-glycero-phosphocholine cycle. Biochim Biophys Acta 1985; 833: 111–118.

    Article  PubMed  CAS  Google Scholar 

  21. Smiley PL, Stremler KE, Prescott SM, Zimmerman GA, McIntyre TM: Oxidatively fragmented phosphatidylcho lines activate human neutrophils through the receptor for platelet-activating factor. J Biol Chem 1991; 266: 11104–11110.

    PubMed  CAS  Google Scholar 

  22. Kunz D, Gerard NP, Gerard C: The human leukocyte platelet-activating factor receptor: cDNA cloning, cell surface expression, and construction of a novel epitope-bearing analog. J Biol Chem 1992; 267: 9101–9106.

    PubMed  CAS  Google Scholar 

  23. Polonsky J, Tence M, Varenne P, Das BC, Lunel J, Benveniste J: Release of 1-O-alkylglyceryl 3-phosphorylcholine, O-deacetyl platelet-activating factor, from leukocytes: chemical ionization mass spectrometry of phospholipids. Proc Natl Acad Sci USA 1980; 77: 7019–7023.

    Article  PubMed  CAS  Google Scholar 

  24. Anderson BO, Bensard DD, Harken AH: The role of platelet activating factor and its antagonists in shock, sepsis and multiple organ failure. Surg Gynecol Obstet 1991; 172: 415–424.

    PubMed  CAS  Google Scholar 

  25. Wykle RL, Miller GH, Lewis JG, et al: Strereospecific activity of 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine and comparison of analogs in the degranulation of platelets and neutrophils. Biochem Biophys Res Commun 1981; 100: 1651–1658.

    Article  PubMed  CAS  Google Scholar 

  26. Ohno M, Fujita K, Shiraiwa M, et al: Molecular design toward biologically significant compounds based on platelet activating factor: a highly selective agonist as a potential antihypertensive agent. J Med Chem 1986; 29: 1812–1814.

    Article  PubMed  CAS  Google Scholar 

  27. Hanahan DJ: Platelet-activating factor: a biologically active phosphoglyceride. Annu Rev Biochem 1986; 55: 483–509.

    Article  PubMed  CAS  Google Scholar 

  28. Anderson BO, Poggetti RS, Shanley PF, et al: Primed neutrophils injure rat lung through a platelet-activating factor-dependent mechanism. Surgery 1991; 109: 51–61.

    PubMed  CAS  Google Scholar 

  29. Camussi G, Tetta C, Bussolino F, Baglioni C: Tumor necrosis factor stimulates human neutrophils to release leukotriene B4 and platelet-activating factor: induction of phospholipase A2 and acetyl-CoA: 1-alkyl-sn-glycero-3-phosphocholine O2-acetyltrans-ferase activity and inhibition by antiproteinase. J Exp Med 1987; 166: 1390–1404.

    Article  PubMed  CAS  Google Scholar 

  30. Whatley RE, Zimmerman GA, McIntyre TM, Prescott SM: Endothelium from diverse vascular sources synthesizes platelet-activating factor. Arteriosclerosis 1988; 8: 321–331.

    Article  PubMed  CAS  Google Scholar 

  31. Whittle BJ, Boughton-Smith NK, Hutcheson IR, Esplugues JV, Wallace JL: Increased intestinal formation of PAF in endotoxin-induced damage in the rat. Br J Pharmacol 1991; 92: 3–4.

    Article  Google Scholar 

  32. Doebber TW, Wu MS: Platelet-activating factor (PAF) stimulates the PAF synthesizing enzyme acetyl-GoA: 1-alkyl-sn-glycero-3-phosphocholine O2-acetyltransferase and PAF synthesis in neutrophils. Proc Natl Acad Sci USA 1987; 84: 7557–7561.

    Article  PubMed  CAS  Google Scholar 

  33. Ingraham LM, Coates TD, Allen JM, Higgins CP, Baehner RL, Boxer LA: Metabolic, membrane, and functional responses of human polymorphonuclear leukocytes to platelet-activating factor. Blood 1982; 59: 1259–1266.

    PubMed  CAS  Google Scholar 

  34. Braquet P, Hosford D, Koltz P, Guilbaud J, Paubert-Braquet M: Effect of platelet-activating factor on tumor necrosis factor-induced superoxide generation from human neutrophils: possible involvement of G proteins. Lipids 1991; 26: 1071–1075.

    Article  PubMed  CAS  Google Scholar 

  35. Nakamura M, Honda Z, Izumi T, et al: Molecular cloning and expression of platelet-activating factor receptor from human leukocytes. J Biol Chem 1991; 266: 20400–20405.

    PubMed  CAS  Google Scholar 

  36. Bussolino F, Camussi G, Aglietta M, et al: Human endothelial cells are target for platelet-activating factor. I. Platelet-activating factor induces changes in cytoskeleton structures. J Immunol 1987; 139: 2439–2446.

    PubMed  CAS  Google Scholar 

  37. Montrucchio G, Alloatti G, Tetta C, et al: Release of platelet-activating factor from ischemic-reperfused rabbit heart. Am J Physiol 1989; 256: H1236–H1246.

    PubMed  CAS  Google Scholar 

  38. Inarrea P, Gomez-Cambronero J, Pascual J, Ponte MC, Hernando L, Sanchez-Crespo M: Synthesis of PAF-acether and blood volume changes in gram-negative sepsis. Immunopharmacology 1985; 9: 45–52.

    Article  PubMed  CAS  Google Scholar 

  39. Doebbcr TW, Wu MS, Robbins JC, Choy BM, Chang MM, Shen TY: Hatelet activating factor (PAF) involvement in endotoxin-induced hypotension hi rats; studies with PAF-reeeptor antago-nist kadsurenone. Biochem Biophys Res Gommun 1985; 127; 799–808.

    Article  Google Scholar 

  40. Dobrowsky RT, Voyksner RD, Olson NC: Effect of SRI 63-675 on hemodynamics and blood PAF levels during porcine endotoxemia. Am J Physiol 1991; 260; H1455–H1465.

    PubMed  CAS  Google Scholar 

  41. Bessin P, Bonnet J, Apffel D, et al: Acute circulatory collapse caused by platelet-activating factor (PAF-acether) in dogs. Eur J Pharmacol 1983; 86: 403–413.

    Article  PubMed  CAS  Google Scholar 

  42. Argiolas L, Fabi F, del BP: Mechanisms of pulmonary vasoconstriction and bronchoconstriction produced by PAF in the guineapig: role of platelets and cyclo-oxygenase metabolites. Br J Pharmacol 1995; 114: 203–209.

    Article  PubMed  CAS  Google Scholar 

  43. Touvay C, Wain B, Taylor JE, Etfenne A, Braquet P: Proof of the involvement of platelet activating factor (PAF-acether) in pulmonary complex immune systems using a specific PAF-acether receptor antagonist: BN 52021. Prog Lipid Res 1985; 25: 277–288.

    Article  Google Scholar 

  44. Smallbone BW, Taylor NE, McDonald JW: Effects of L-652, 731, a platelet-activating factor (PAF) receptor antagonist, on PAF-andcomplement-induced pulmonary hypertension in sheep. J Phamacol Exp Ther 1987; 242: 1035–1040.

    CAS  Google Scholar 

  45. Botha AJ, Moore FA, Moore EE, Peterson VM, Silliman CC, Goode AW: Sequential systemic platelet-activating factor and interleukin 8 primes neutrophils in patients at risk of multiple organ failure. Br J Surg 1996; 83: 1407–1412.

    Article  PubMed  CAS  Google Scholar 

  46. Bussolino F, Porcellini MG, Varese L, Bosia A: Intravascular release of platelet activating factor in children with sepsis. Thromb Res 1987; 48: 619–620.

    Article  PubMed  CAS  Google Scholar 

  47. Terashita Z, Tsushima S, Yoshioka Y, Nomura H, Inada Y, Nishikawa K: CV-3988: a specific antagonist of platelet activating factor (PAF). life Sci 1983; 32: 1975–1982.

    Article  Google Scholar 

  48. Terashita Z, Takatani M, Tsushima S, Mshikawa K; CV-6209: a highly potent platelet-activating factor (PAF) antagonist [abstract]. Presented at the Second International Congress on Platelet-Activating Factor and Structurally Related Alkyl Ether Lipids 1986; 29..

    Google Scholar 

  49. Terashita Z, Kawamura M, Takatani M, Tsushima S, Imura Y, Nishikawa K: Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents. J Pharmacol Exp Ther 1992; 260: 748–755.

    PubMed  CAS  Google Scholar 

  50. Miyamoto T, Ohno M, Yano T, Okada T, Hamanaka N, Kawasaki A: ONO-6420: a new potent antagonist of plateletactivating factor [abstract]. Adv Prostaglandin Thromboxane Leukotriene Res 1985; 15: 719–720.

    Google Scholar 

  51. Burri K, Barner R, Cassal J-M, Hadvary P, Hirth G, Müller K: PAF: from agonists to antagonists by synthesis. Prostaglandins 1985; 30: 691.

    Google Scholar 

  52. Handley DA, Anderson RC, Saunders RN: Inhibition by SRI 63-072 and SRI 63-119 of PAF-acether and immune complex effects in the guinea pig. Eur J Pharmacol 1987; 141: 409–416.

    Article  PubMed  CAS  Google Scholar 

  53. Winslow CM, Vallespir SR, Frisch GE, et al: A novel platelet activating factor receptor antagonist. Prostaglandins 1985; 30: 697.

    Google Scholar 

  54. Wichrowski B, Jouquey S, Heymans F, et al: Platelet activating factor analogs from agonists to antagonists by synthesis by carboxylate isosters [abstract]. Presented at the Sixth International Conference on Prostaglandins and Related Compounds 1986; 309.

    Google Scholar 

  55. Patterson R, Harris KE, Lee ML, Houlihan WJ: Inhibition of rhesus monkey airway and cutaneous responses to plateletactivating factor (PAF) (AGEPC) with the anti-PAF agent SRI 63-072 [abstract]. Int Arch Allergy Immunol 1986; 81: 265–268.

    Article  CAS  Google Scholar 

  56. Handley DA, Tomesch JC, Saunders RN: Inhibition of PAF-induced systemic responses in the rat, guinea pig, dog and primate by the receptor antagonist SRI 63-441. Thromb Haemost 1986; 56: 40–44.

    PubMed  CAS  Google Scholar 

  57. Sanchez CM, Fernandez GS, Nieto ML, Baranes J, Braquet P: Inhibition of the vascular actions of IgG aggregates by BN 52021, a highly specific antagonist of PAF-acether. Immunopharmacology 1985; 10: 67–75.

    Google Scholar 

  58. Dhainaut JF, Tenaillon A, Hemmer M, et al: Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial: BN 52021 Sepsis Investigator Group. Crit Care Med 1998; 26: 1963–1971.

    Article  PubMed  CAS  Google Scholar 

  59. Lachachi H, Plantavid M, Simon MF, Chap H, Braquet P, Douste BL; Inhibition of transmembrane movement and metabolism of platelet activating factor (PAF-acether) by a specific antagonist, BN 52021. Biochem Biophys Res Commun 1985; 132: 460–466.

    Article  PubMed  CAS  Google Scholar 

  60. Wu MS, Biftu T, Doebber TW: Inhibition of the platelet activating factor (PAF)-induced in vivo responses in rats by trans2, 5-(3, 4, 5-trimethoxyphenyl) tetrahydrofuran (L-652, 731), a PAF receptor antagonist. J Pharmacol Exp Ther 1986; 239: 841–845.

    PubMed  CAS  Google Scholar 

  61. Okamoto M, Yoshida K, Nishikawa M, Kohsaka M, Aoki H: Platelet activating factor (PAF) involvement in endotoxin-induced thrombocytopenia in rabbits: studies with FR-900452, a specific inhibitor of PAF. Thromb Res 1986; 42: 661–671.

    Article  PubMed  CAS  Google Scholar 

  62. Okamoto M, Yoshida K, Uchida I, Kohsaka M, Aoki H: Studies of platelet activating factor (PAF) antagonists from microbial products. II. Pharmacological studies of FR-49175 in animal models. Ghem Pharm Bull Tokyo 1986; 34: 345–348.

    Article  CAS  Google Scholar 

  63. Casals SJ, Muacevic G, Weber KH: Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor. J Pharmacol Exp Ther 1987; 241: 974–981.

    Google Scholar 

  64. Brambilla A, Ghiorzi A, Giachetti A: WEB 2086: a potent PAF antagonist exerts protective effect toward PAF-induced gastric damage. Pharmacol Res Commun 1987; 19: 147–151.

    Article  PubMed  CAS  Google Scholar 

  65. Casals SJ: Protective effect of WEB 2086, a novel antagonist of platelet activating factor, in endotoxin shock. Eur J Pharmacol 1987; 135: 117–122.

    Article  Google Scholar 

  66. Ogata M, Matsumoto T, Koga K, et al: An antagonist of platelet-activating factor suppresses endotoxin-induced tumor necrosis factor and mortality in mice pretreated with carrageenan. Infect Immun 1993; 61: 699–704.

    PubMed  CAS  Google Scholar 

  67. Yue TL, Farhat M, Rabinovici R, Perera PY, Vogel SN, Feuerstein G: Protective effect of BN 50739, a new platelet-activating factor antagonist, in endotoxin-treated rabbits. J Pharmacol Exp Ther 1990; 254: 976–981.

    PubMed  CAS  Google Scholar 

  68. Kuipers B, vanderPoll T, Levi M, et al: Platelet-activating factor antagonist TCV-309 attenuates the induction of the cytokine network in experimental endotoxemia in chimpanzees. J Immunol 1994; 152: 2438–2246

    PubMed  CAS  Google Scholar 

  69. Spapen H, Zhang H, Verhaeghe V, Smail N, Vincent JL: The platelet-activating factor antagonist BB-882 does not improve tissue oxygen extraction in endotoxic shock. J Crit Care 1998; 13: 81–90.

    Article  PubMed  CAS  Google Scholar 

  70. Ou MG, Kambayashi J, Kawasaki T, et al: Potential etiologic role of PAF in two major septic complications; disseminated infravas-60. cular coagulation and multiple organ failure. Thromb Res 1994; 73: 227–238.

    Article  PubMed  CAS  Google Scholar 

  71. Murakami K, Okajima K, Uchiba M, Johno M, Okabe H, Takatsuki K: A novel platelet activating factor antagonist, SM-12502, attenuates endotoxin-induced disseminated intravascular coagulation and acute pulmonary vascular injury by inhibiting TNF production in rats. Thromb Haemost 1996; 75: 965–970.

    PubMed  CAS  Google Scholar 

  72. Spapen H, Zhang H, Verhaeghe V, Rogiers P, Cabral A, Vincent JL: Treatment with a platelet-activating factor antagonist has little protective effects during endotoxic shock in the dog. Shock 1997; 8: 200–206.

    Article  PubMed  CAS  Google Scholar 

  73. Mathiak G, Szewczyk D, Abdullah F, Ovadia P, Rabinovici R: Platelet-activating factor (PAF) in experimental and clinical sepsis. Shock 1997; 7: 391–404.

    Article  PubMed  CAS  Google Scholar 

  74. Olson NC, Joyce PB, Fleisher LN: Role of platelet-activating factor and eicosanoids during endotoxin-mduced lung injury in pigs. Am J Physiol 1990; 258: H1674–H186.

    PubMed  CAS  Google Scholar 

  75. Siebeck M, Weipert J, Keser C, et al: A triazolodiazepine platelet activating factor receptor antagonist (WEB 2086) reduces pulmonary dysfunction during endotoxin shock in swine. J Trauma 1991; 31: 942–949.

    Article  PubMed  CAS  Google Scholar 

  76. Chang SW, Fernyak S, Voelkel NF: Beneficial effect of a platelet-activating factor antagonist, WEB 2086, on endotoxin-induced lung injury. Am J Physiol 1990; 258: H153–H158.

    PubMed  CAS  Google Scholar 

  77. Makristathis A, Stauffer F, Feistauer SM, Georgopoulos A: Bacteria induce release of platelet-activating factor (PAF) from polymorphonuclear neutrophil granulocytes: possible role for PAF in pathogenesis of experimentally induced bacterial pneumonia. Infect Immun 1993; 61: 1996–2002.

    PubMed  CAS  Google Scholar 

  78. Gupta JB, Prasad M, Kalra J, Prasad K: Platelet-activating-factor-induced changes in cardiovascular function and oxyradical status of myocardium in presence of the PAF antagonist CV-6209. Angiology 1994; 45: 25–36.

    Article  PubMed  CAS  Google Scholar 

  79. Adams DH, Nash GB: Disturbances of leucocyte circulation and adhesion to the endothelium as factors in circulatory pathology. Br J Anaesth 1996; 77: 17–31.

    Article  PubMed  CAS  Google Scholar 

  80. Coughlan AF, Hau H, Dunlop LC, Berndt MC, Hancock WW: P-selectin and platelet-activating factor mediate initial endotoxin-induced neutropenia. J Exp Med 1994; 179: 329–334.

    Article  PubMed  CAS  Google Scholar 

  81. Kubes P, Ibbotson G, Russell J, Wallace JL, Granger DN: Role of platelet-activating factor in ischemia/reperfusion-induced leukocyte adherence. Am J Physiol 1990; 259: G300–G305.

    PubMed  CAS  Google Scholar 

  82. Yin M, Kurvers HAJM, Buurman WA, et al: Beneficial effect of platelet-activating factor antagonist TCV-309 on renal ischemia-reperfusion injury. Transplant Proc 1995; 27: 774–776.

    PubMed  CAS  Google Scholar 

  83. Wallace JL, Hogaboam CM, McKnight GW: Platelet-activating factor mediates gastric damage induced by hemorrhagic shock. Am J Physiol 1990; 259: G140–G146.

    PubMed  CAS  Google Scholar 

  84. Fink MP: Gastrointestinal mucosal injury in experimental models of shock, trauma, and sepsis. Crit Care Med 1991; 19: 627–641.

    Article  PubMed  CAS  Google Scholar 

  85. Biffl WL, Moore EE: Splanchnic ischaemia/reperfusion and multiple organ failure. Br J Anaesth 1996; 77: 59–70.

    Article  PubMed  CAS  Google Scholar 

  86. Wallace JL, Steel G, Whittle BJR, Lagente V, Vargaftig B: Evidence for platelet-activating factor as a mediator of endotoxin-induced gastrointestinal damage in the rat: effects of three platelet-activating factor antagonists. Gastroenterology 1987; 93: 765–773.

    PubMed  CAS  Google Scholar 

  87. Meenan J, Grool TA, Hommes DW, et al: Lexipafant (BB-882), a platelet activating factor receptor antagonist, ameliorates mucosal inflammation in an animal model of colitis. Eur J Gastroenterol Hepatol 1996; 8: 569–573.

    Article  PubMed  CAS  Google Scholar 

  88. Hofbauer B, Saluja AK, Bhatia M, et al: Effect of recombinant platelet-activating factor aeetylhydrolase on two models of experimental acute pancreatitis. Gastroenterology 1998; 115: 1238–1247.

    Article  PubMed  CAS  Google Scholar 

  89. Yamano M, Umeda M, Miyata K, Yamada T: Protective effects of a PAF receptor antagonist and a neutrophil elastase inhibitor on multiple organ failure induced by cerulein plus lipopolysac-charide in rats. Naunyn Schmiedebergs Arch Pharmacol 1998; 358: 253–263.

    Article  PubMed  CAS  Google Scholar 

  90. Andersson R, Wang XD, Sun ZW, Deng XM, Soltesz V, Ihse I: Effect of a platelet-activating factor antagonist on pancreatitisassociated gut barrier dysfunction in rats. Pancreas 1998; 17: 107–119.

    Article  PubMed  CAS  Google Scholar 

  91. Sorensen J, Kald B, Tagesson C, Lindahl M: Platelet-activating factor and phospholipase A2 in patients with septic shock and trauma. Intensive Care Med 1994; 20: 555–561.

    Article  PubMed  CAS  Google Scholar 

  92. Ono S, Tamakuma S, Mochizuki H, et al: Clinical and experimental studies on the role of platelet-activating factor (PAF) in the pathogenesis of septic DIG. Surg Today 1993; 23: 228–233.

    Article  PubMed  CAS  Google Scholar 

  93. Heuer HO, Darius H, Lohmann HF, Meyer J, Schierenberg M, Treese N: Platelet-activating factor type activity in plasma from patients with septicemia and other diseases. Lipids 1991; 26: 1381–1385.

    Article  PubMed  CAS  Google Scholar 

  94. Lopez DF, Nieto ML, Fernandez-Gallardo S, Gijon MA, Sanchez CM: Occupancy of platelet receptors for platelet-activating factor in patients with septicemia. J Glin Invest 1989; 83: 1733–1740.

    Article  Google Scholar 

  95. Bussolino F, Porcellini MG, Varese L, Bosia A: Intravascular release of platelet activating factor in children with sepsis [letter]. Thromb Res 1987; 48: 619–620.

    Article  PubMed  CAS  Google Scholar 

  96. Shinozaki K, Kawasaki T, Kambayashi J, et al: A new method of purification and sensitive bioassay of platelet-activating factor (PAF) in human whole Mood. life Sri 1994; 54: 429–437.

    Article  CAS  Google Scholar 

  97. Thompson WA, Coyle S, VanZee K, et al: The metabolic effects of platelet-activating factor antagonism in endotoxemic man. Arch Surg 1994; 129: 72–79.

    Article  PubMed  CAS  Google Scholar 

  98. Dhainaut J-F, Mira J-P, Brunet F: Platelet-activating factor antagonists as therapeutic strategy in sepsis. In: Anonymous Bacterial Endotoxins: Basic Science to Anti-sepsis Strategies, 1st ed. New York, Wiley-Iiss 1994; 277–293.

    Google Scholar 

  99. Froon AM, Greve JW, Buurman WA, et al: Treatment with the platelet-activating factor antagonist TCV-309 in patients with severe systemic inflammatory response syndrome: a prospective, multi-center, double-blind, randomized phase II trial. Shock 1996; 5: 313–319.

    Article  PubMed  CAS  Google Scholar 

  100. Poeze M, Froon AHM, Ramsay G, Buurman WA, Greve JW: Organ failure and MOF-related death is reduced in patients with septic shock treated with the PAF-antagonist TCV-309. Intensive Care Med 1998; 24(Suppl 1): S69.

    Google Scholar 

  101. Kingsnorth AN, Galloway SW, Formela LJ: Randomized, double-blind phase II trial of lexipafant, a platelet-activating factor antagonist, in human acute pancreatitis. Br J Surg 1995; 82: 1414–1420.

    Article  PubMed  CAS  Google Scholar 

  102. Kingsnorth AN, British Acute Pancreatitis Study Group: Early treatment with lexipafant, a platelet activating factor antagonist reduces mortality in acute pancreatitis: a double blind, randomized, placebo controlled study [abstract]. Gastroenterology 1997; 112: A453.

    Google Scholar 

Download references

Authors
  1. M. Poeze
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. A. Buurman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Ramsay
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. W. M. Greve
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Surgery, St. Louis University Hospital, St. Louis, Missouri, 63110, USA

    Arthur E. Baue MD (Professor Emeritus) (Professor Emeritus)

  2. Department of Surgery, Klinikum Grosshadern, University of Munich, Munich, D-81377, Germany

    Eugen Faist MD (Professor) (Professor)

  3. Department of Surgery, School of Medicine, University of New Mexico, Albuquerque, New Mexico, 87131, USA

    Donald E. Fry MD (Professor and Chairman) (Professor and Chairman)

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer Science+Business Media New York

About this chapter

Cite this chapter

Poeze, M., Buurman, W.A., Ramsay, G., Greve, J.W.M. (2000). Platelet-Activating Factor. In: Baue, A.E., Faist, E., Fry, D.E. (eds) Multiple Organ Failure. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-1222-5_22

Download citation

  • DOI: https://doi.org/10.1007/978-1-4612-1222-5_22

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4612-7049-2

  • Online ISBN: 978-1-4612-1222-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation